<PAGE> 1
===============================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20594
---------------------
(Mark One)
/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended June 30, 1998
OR
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ______________________ to _______________________
Commission File Number 0-19371
[PHARMCHEM LABORATORIES, INC. LOGO]
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
CALIFORNIA 77-0187280
(State or other jurisdiction (IRS Employer
of incorporation or organization) Identification Number)
1505-A O'BRIEN DRIVE
MENLO PARK, CALIFORNIA 94025
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (650) 328-6200
</TABLE>
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such report(s), and (2) has been subject to such
filing requirements for the past 90 days. Yes ___ No ____
As of July 31, 1998, the registrant had outstanding 5,764,185 shares of
Common Stock, no par value.
================================================================================
<PAGE> 2
PHARMCHEM LABORATORIES, INC.
QUARTERLY REPORT ON FORM 10-Q
INDEX
<TABLE>
<S> <C> <C>
PAGE
PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements ................................3
Condensed Consolidated Balance Sheets at
June 30, 1998 (unaudited) and December 31, 1997 (audited)...................4
Condensed Consolidated Statements of Operations
(unaudited) for the Three and Six Months ended
June 30, 1998 and 1997......................................................5
Condensed Consolidated Statements of Comprehensive Income (Loss)
(unaudited) for the Three and Six Months ended
June 30, 1998 and 1997......................................................6
Condensed Consolidated Statements of
Cash Flows (unaudited) for the Six Months ended
June 30, 1998 and 1997 ....................................................7
Notes to Condensed Consolidated Financial Statements (unaudited)............8
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations ..................................................9
PART II. OTHER INFORMATION
Item 4. Submission of Matters to a Vote of Security Holders ......................13
Item 6. Exhibits and Reports on Form 8-K .........................................13
SIGNATURE ...........................................................................14
</TABLE>
2
<PAGE> 3
PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
The condensed consolidated financial statements included herein have
been prepared by the Company, without audit, pursuant to the rules and
regulations of the Securities and Exchange Commission. Certain information and
footnote disclosures normally included in financial statements prepared in
accordance with generally accepted accounting principles have been condensed or
omitted pursuant to such rules and regulations, although the Company believes
that the disclosures made are adequate to make the information presented not
misleading. It is suggested that the condensed consolidated financial statements
be read in conjunction with the consolidated financial statements and the notes
thereto for the year ended December 31, 1997 included in the Company's Annual
Report on Form 10-K.
These financial statements have been prepared in all material respects
in conformity with the standards of accounting measurements set forth in
Accounting Principles Board Opinion No. 28, "Interim Financial Reporting," and
the rules and regulations as specified in the Securities Exchange Act of 1934
and reflect all adjustments, consisting only of normal recurring adjustments
which, in the opinion of management, are necessary to summarize fairly the
Company's consolidated financial position, the results of operations and cash
flows for the periods presented. The results of operations for such interim
periods are not necessarily indicative of the results to be expected for the
full year.
3
<PAGE> 4
PHARMCHEM LABORATORIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
<TABLE>
<CAPTION>
June 30, December 31,
1998 1997
----------- -----------
(Unaudited) (Audited)
<S> <C> <C>
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 604 $ 372
Accounts receivable, net 8,620 7,608
Inventory 1,570 1,609
Prepaids and other current assets 513 456
------ ------
TOTAL CURRENT ASSETS 11,307 10,045
------ ------
PROPERTY AND EQUIPMENT, net 8,035 7,788
OTHER ASSETS 1,231 1,238
GOODWILL, net 3,083 3,175
------ ------
TOTAL ASSETS $ 23,656 $ 22,246
====== ======
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Revolving line of credit $ 4,470 $ 4,081
Current portion of long-term debt 392 503
Accounts payable 3,516 3,322
Accrued compensation 812 990
Accrued collectors and other liabilities 3,127 2,296
------ ------
TOTAL CURRENT LIABILITIES 12,317 11,192
------ ------
LONG-TERM DEBT, net of current portion 530 696
OTHER NONCURRENT LIABILITIES 501 147
SHAREHOLDERS' EQUITY
Common stock, no par value, 10,000 shares authorized, 5,764
and 5,750 shares issued and outstanding at June 30, 1998
and December 31, 1997, respectively 19,055 19,027
Accumulated other comprehensive income 97 82
Accumulated deficit (8,844) (8,898)
------ ------
TOTAL SHAREHOLDERS' EQUITY 10,308 10,211
====== ======
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 23,656 $ 22,246
====== ======
</TABLE>
The accompanying notes are an integral part of these condensed consolidated
financial statements.
4
<PAGE> 5
PHARMCHEM LABORATORIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share amounts)
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
June 30, June 30,
------------------------ -------------------------
1998 1997 1998 1997
---------- ---------- ---------- -----------
<S> <C> <C> <C> <C>
NET SALES $ 11,451 $ 10,003 $ 20,979 $ 19,061
COST OF SALES 8,215 8,014 15,523 15,170
---------- ---------- ---------- -----------
GROSS PROFIT 3,236 1,989 5,456 3,891
OPERATING EXPENSES
Selling, general and administrative 2,804 2,029 5,012 4,092
Marketing rights and research 13 83 40 167
Amortization of goodwill 46 46 92 92
---------- ---------- ---------- -----------
Total operating expenses 2,863 2,158 5,144 4,351
---------- ---------- ---------- -----------
INCOME (LOSS) FROM OPERATIONS 373 (169) 312 (460)
Interest expense 90 99 189 184
Other expense (income), net (9) (1) (12) 1
---------- ---------- ---------- -----------
Total other expenses 81 98 177 185
---------- ---------- ---------- -----------
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES 292 (267) 135 (645)
PROVISION FOR INCOME TAXES 46 - 81 -
---------- ---------- ---------- -----------
NET INCOME (LOSS) $ 246 $ (267) $ 54 $ (645)
========== ========== ========== ===========
EARNINGS (LOSS) PER SHARE:
Basic $ 0.04 $ (0.05) $ 0.01 $ (0.11)
========== ========== ========== ===========
Diluted $ 0.04 $ (0.05) $ 0.01 $ (0.11)
========== ========== ========== ===========
WEIGHTED AVERAGE SHARES OUTSTANDING:
Basic 5,758 5,719 5,754 5,722
========== ========== ========== ===========
Diluted 5,826 5,719 5,821 5,722
========== ========== ========== ===========
</TABLE>
The accompanying notes are an integral part of these condensed consolidated
financial statements.
5
<PAGE> 6
PHARMCHEM LABORATORIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited)
(In thousands)
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
June 30, June 30,
------------------------ -------------------------
1998 1997 1998 1997
---------- ---------- ---------- -----------
<S> <C> <C> <C> <C>
NET INCOME (LOSS) $ 246 $ (267) $ 54 $ (645)
OTHER COMPREHENSIVE INCOME:
Foreign currency translation (1) 5 15 10
---------- ---------- ---------- -----------
COMPREHENSIVE INCOME (LOSS) $ 245 $ (262) $ 69 $ (635)
========== ========== ========== ===========
</TABLE>
The accompanying notes are an integral part of these condensed consolidated
financial statements.
6
<PAGE> 7
PHARMCHEM LABORATORIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
Six Months Ended
June 30,
----------------------
1998 1997
--------- ---------
(In thousands)
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ 54 (645)
Adjustments to reconcile net income (loss) to net cash provided by
operating activities:
Depreciation and amortization 995 956
Provision for doubtful accounts 93 78
Loss on disposition of property and equipment - 2
Changes in operating assets and liabilities:
Accounts receivable (1,105) 233
Inventory 39 (771)
Prepaids and other current assets (57) 259
Other assets 7 (14)
Accounts payable and other accrued liabilities 847 (136)
Other noncurrent liabilities 354 16
-------- -------
Net cash provided by (used in) operating activities 1,227 $ (22)
-------- -------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment (1,150) (1,099)
-------- -------
Net cash used in investing activities (1,150) (1,099)
-------- -------
CASH FLOWS FROM FINANCING ACTIVITIES:
Borrowings (repayments) on revolving lines of credit, net 389 1,788
Principal payments on long-term debt (277) (691)
Proceeds from exercise of stock options 28 81
-------- -------
Net cash provided by financing activities 140 1,178
-------- -------
FOREIGN CURRENCY TRANSLATION 15 10
-------- -------
NET INCREASE IN CASH AND CASH EQUIVALENTS 232 67
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 372 240
-------- -------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 604 $ 307
======== =======
</TABLE>
The accompanying notes are an integral part of these condensed consolidated
financial statements.
7
<PAGE> 8
PHARMCHEM LABORATORIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Earnings (Loss) per Share
In the fourth quarter of 1997, the Company adopted Statement of
Financial Accounting Standards ("SFAS") No. 128 "Earnings Per Share." Earnings
(loss) per share amounts for all previously reported periods have been restated
to conform with SFAS No. 128. Basic earnings (loss) per share is calculated
using the weighted average number of common shares outstanding during the
period. Diluted earnings (loss) per share is calculated using the weighted
average number of common shares and dilutive potential common shares outstanding
during the period. Dilutive potential common shares represent shares issuable
upon the exercise of outstanding options and are calculated using the treasury
stock method. Options to purchase shares of the Company's common stock for the
three and six months ended June 30, 1997 were not included in the computation of
diluted earnings per share because their effect would have been antidilutive.
Options to purchase 90,000 shares of the Company's common stock at June 30, 1998
were not included in the computation of diluted earnings per share because their
exercise prices were greater than the average market price of the Company's
common stock of $2.50 per share. Dilutive options of 68,000 and 67,000 were used
in the computation of earnings per share for the three and six month periods
ending June 30, 1998, respectively.
Effective March 24, 1998, the Company engaged in a stock option
exchange program that repriced substantially all then outstanding options having
an exercise price above the then current market price of $2.375. The repriced
options began vesting April 24, 1998 over a 48 month period. The exercise price
for all 463,480 options exchanged was $2.375.
2. Inventory
Inventory represents laboratory materials, collection materials and
products and is stated at the lower of cost or market. Cost is determined using
standard costs, including freight, that approximate actual costs on a first-in,
first-out basis. Inventory consisted of the following at June 30, 1998 and
December 31, 1997, respectively:
<TABLE>
<CAPTION>
1998 1997
---- ----
(In thousands)
<S> <C> <C>
Laboratory materials ............... $ 456 $ 412
Collection materials.. ............. 913 1,072
Products............................ 201 125
----- -----
$1,570 $1,609
===== =====
</TABLE>
3. Debt
PharmChem maintains a revolving line of credit agreement ("Credit
Agreement") with a bank. At June 30, 1998, the maximum that could be borrowed
under the Credit Agreement was $6,000,000 and $4,470,000 was outstanding under
the Credit Agreement.
8
<PAGE> 9
4. New Accounting Pronouncements
The Company has adopted Statement of Financial Accounting Standards
("SFAS") No. 130 "Reporting Comprehensive Income." Comprehensive income (loss)
includes net income (loss) and several other items that current accounting
standards require to be recognized outside of net income (loss).
5. Reclassifications
Certain reclassifications have been made to prior period amounts to
conform to current year presentation.
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
FORWARD LOOKING STATEMENTS
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934 and Section 27A of the
Securities Act of 1933, which are subject to the "safe harbor" created by these
Sections. The Company's actual future results could differ materially from those
projected in the forward-looking statements. Some factors which could cause
future actual results to differ materially from the Company's recent results and
those projected in the forward-looking statements are described in the Company's
Annual Report on Form 10-K for the year ended December 31, 1997. The Company
assumes no obligation to update the forward-looking statements or such factors.
9
<PAGE> 10
RESULTS OF OPERATIONS
The following table sets forth for the periods indicated certain
financial data (dollars in thousands):
<TABLE>
<CAPTION>
Three Months Ended June 30, Six Months Ended June 30,
--------------------------------------- -----------------------------------------
1998 1997 1998 1997 1998 1997 1998 1997
--------- -------- --------- --------- ---------- -------- -------- ----------
(As a % of net sales) (As a % of net sales)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
NET SALES:
Public and private employers $4,871 $4,533 42.5% 45.3% $8,488 $8,362 40.5% 43.9%
Criminal justice agencies 3,704 3,854 32.3 38.6 7,269 7,462 34.6 39.1
Drug rehabilitation programs 452 363 4.0 3.6 780 749 3.7 3.9
Domestic product sales 736 161 6.4 1.6 1,200 419 5.7 2.2
Medscreen 1,688 1,092 14.8 10.9 3,242 2,069 15.5 10.9
--------- -------- --------- --------- --------- -------- --------- ---------
Total net sales 11,451 10,003 100.0 100.0 20,979 19,061 100.0 100.0
COST OF SALES 8,215 8,014 71.7 80.1 15,523 15,170 74.0 79.6
--------- -------- --------- --------- --------- -------- --------- ---------
GROSS PROFIT 3,236 1,989 28.3 19.9 5,456 3,891 26.0 20.4
--------- -------- --------- --------- --------- -------- --------- ---------
OPERATING EXPENSES:
Selling, general and administrative 2,804 2,029 24.5 20.3 5,012 4,092 23.9 21.4
Marketing rights and research 13 83 0.1 0.8 40 167 0.2 0.9
Amortization of goodwill 46 46 0.4 0.5 92 92 0.4 0.5
--------- -------- --------- ---------
--------- -------- --------- ---------
Total operating expenses 2,863 2,158 25.0 21.6 5,144 4,351 24.5 22.8
--------- -------- --------- --------- --------- -------- --------- ---------
INCOME (LOSS) FROM OPERATIONS 373 (169) 3.3 (1.7) 312 (460) 1.5 (2.4)
--------- -------- --------- --------- --------- -------- --------- ---------
OTHER EXPENSES, net 81 98 0.8 1.0 177 185 0.8 1.0
PROVISION FOR INCOME TAXES 46 - 0.4 - 81 - 0.4 -
--------- -------- --------- --------- --------- -------- --------- ---------
NET INCOME (LOSS) $ 246 $(267) 2.1% (2.7)% $ 54 $(645) 0.3% (3.4)%
========= ======== ========= ========= ========= ======== ========= =========
</TABLE>
Net sales for the three months ended June 30, 1998 increased $1,448,000
(14.5%) to $11,451,000 in 1998 from $10,003,000 in 1997. Medscreen, the
Company's U.K. operation, reported a sales increase of $596,000 (54.6%)
primarily attributed to awarding of the drug-testing contract for H.M Prisons,
one of the largest agencies that conducts drug testing outside of the United
States, and higher maritime collection accounts throughout the world. Domestic
urinalysis revenues increased $277,000 (3.2%) principally from public and
private employers and higher average selling prices of 4.4%. The Company's
domestic specimen volume was relatively unchanged from 1997 levels.
PharmScreenTM On-site Screening Devices sales increased five-fold due to
continued strong demand and the introduction of an expanded product line, while
sales of the PharmChek(R) Drugs of Abuse Patch increased $142,000 compared to
the prior year period.
Net sales for the six months ended June 30, 1998 increased $1,918,000
(10.1%) to $20,979,000 in 1998 from $19,061,000 in 1997, principally due to a
sales increase of $1,173,000 (56.7%) at Medscreen and higher domestic product
sales of $781,000 (186.4%). Domestic average selling prices increased 4.1% while
specimen volume decreased 3.5%.
Cost of sales for the three months ended June 30, 1998 increased
$201,000 (2.5%) to $8,215,000 in 1998 from $8,014,000 in 1997. Cost of sales as
a percentage of net sales decreased to 71.7% in 1998 from 80.1% in 1997. Gross
profit as a percentage of net sales increased to 28.3% in 1998 from 19.9% in
1997, reflecting the higher margin on product sales, lower labor costs and
increased efficiencies.
10
<PAGE> 11
Cost of sales for the six months ended June 30, 1998 increased $353,000
(2.3%) to $15,523,000 in 1998 from $15,170,000 in 1997. Cost of sales as a
percentage of net sales decreased to 74.0% in 1998 from 79.6% in 1997. Gross
profit as a percentage of net sales increased to 26.0% in 1998 from 20.4% in
1997, reflecting the higher margin on product sales, lower labor costs and
increased efficiencies.
Selling, general and administrative (SG&A) expenses for the three
months ended June 30, 1998 increased $775,000 (38.2%) to $2,804,000 in 1998 from
$2,029,000 in 1997. SG&A expenses as a percentage of net sales increased to
24.5% in 1998 from 20.3% in 1997.
SG&A expenses for the six months ended June 30, 1998 increased $920,000
(22.5%) to $5,012,000 in 1998 from $4,092,000 in 1997. SG&A expenses as a
percentage of net sales increased to 23.9% in 1998 from 21.4% in 1997. The
increase in SG&A expenses for the quarter and for the year-to-date periods
represents higher information systems expenditures and continued rebuilding of
the sales, marketing and administrative infrastructure.
Income from operations for the three months ended June 30, 1998 was
$373,000 compared to a loss of $169,000 for the comparable period in 1997.
Income from operations for the six months ended June 30, 1998 was $312,000
compared to a loss of $460,000 for the comparable period in 1997. The Company
recorded a provision for income taxes of $46,000 for the second quarter and of
$81,000 for the six month period ending June 30, 1998, attributed to its UK
operations.
Net income for the three months ended June 30, 1998 was $246,000 or
$0.04 per diluted share in 1998 compared to a loss of $267,000 or $0.05 per
diluted share in 1997. Net income for the six months ended June 30, 1998 was
$54,000 or $0.01 per diluted share in 1998 compared to a loss of $645,000 or
$0.11 per diluted share in 1997.
LIQUIDITY AND CAPITAL RESOURCES
The Company's operations during the six month period ended June 30
provided cash of approximately $1,227,000 in 1998 and used cash of $22,000 in
1997. The improvement in cash flow from operations between 1998 and 1997
principally reflects the current period's net income and lower inventory levels.
As of June 30, 1998, the Company had $604,000 in cash and cash equivalents.
During the six months ended June 30, 1998, the Company used approximately
$1,150,000 in cash to acquire property and equipment, principally for
information systems and laboratory equipment.
The Company maintains a Credit Agreement with a bank. All borrowings
are secured by a lien on all assets of the Company. The Credit Agreement
provides for borrowings under the revolver limited to 85% of qualified accounts
receivables up to a maximum of $6,000,000. At June 30, 1998, the maximum that
could be borrowed was $6,000,000 and approximately $4,470,000 was outstanding
under the Credit Agreement. Year-to-date net borrowings on the revolver were
approximately $389,000 as of June 30, 1998. The Credit Agreement contains
certain financial covenants which, among others, require the Company to maintain
certain levels of net worth, cash flow and profitability, and restricts the
payment of dividends. As of June 30, 1998, the Company was in compliance with
its financial covenants.
11
<PAGE> 12
The Company anticipates that existing cash balances, amounts available
under existing and future credit agreements and funds to be generated from
future operations will be sufficient to fund operations and forecasted capital
expenditures through 1998.
IMPACT OF RECENT ACCOUNTING PRONOUNCEMENTS
In June 1997, the FASB issued SFAS No. 130 "Reporting Comprehensive
Income." SFAS No. 130 establishes standards for reporting and displaying
comprehensive income and its components in general-purpose financial statements
and is effective for fiscal years beginning after December 15, 1997.
Comprehensive income includes net income and several other items that current
accounting standards require to be recognized outside of net income. The Company
adopted the SFAS No. 130 disclosures in its 1998 consolidated financial
statements.
YEAR 2000
The Company is subject to various risks associated with the Year 2000
("Y2K") impact on information systems. External risk factors are principally
related to the ability of the Company's customers and suppliers to address Y2K
issues that may adversely impact the Company's operations if not corrected. The
Company has performed a preliminary assessment of the Y2K impact on internal
information systems. The assessment identified Y2K issues with respect to the
Company's laboratory information system which may require either a significant
investment in programming maintenance because of the existence of a legacy flat
file system or in the replacement of the existing system. The company is
evaluating enhanced capabilities of new laboratory information systems offering
a more current technological architecture and related costs and expects to
arrive at a decision later this year.
Due to the large volume of electronic transmissions, the Company is
also conducting inquiries of customers and key business partners to identify Y2K
issues. The Company has contacted all of its critical vendors informing them it
will require written confirmation that such vendors can be Y2K compliant by the
end of 1998. In addition, the Company plans, at the beginning of 1999, to
commence transmission of test results to its customers using a four digit year
to determine which customers can and cannot receive such electronic results with
a year field of four digits.
Since embarking on the Y2K compliance program, the Company has incurred
approximately $50,000 of expense and believes a similar amount will be incurred
in each of the next three six-month periods. This estimate excludes any costs
necessary to re-program or replace the laboratory information system described
above. It should be noted that a major portion of investments in property and
equipment during the last 30 months has been to rebuild the infrastructure in
computer hardware and software. This replacement of hardware and software
included Y2K compliance for various systems.
12
<PAGE> 13
PART II. OTHER INFORMATION
Item 4. Submission of Matters to a Vote of Security Holders
At the Annual Meeting of the Company held on May 19, 1998, the
Company's shareholders took the following actions:
(a) The following directors were elected to serve until the next Annual
Meeting:
Joseph W. Halligan - 5,167,770 shares in favor and 92,881 shares
withheld;. Richard D. Irwin - 5,179,410 shares in favor and 81,241
shares withheld; and Donald R. Stroben - 5,168,770 shares in favor and
91,881 shares withheld.
(b) Ratification of the appointment of KPMG Peat Marwick LLP as
Independent Public Accountants for the Company for the 1998 fiscal
year, by a vote of 5,236,854 shares in favor, 8,720 shares against
and 15,077 shares abstained.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits:
Exhibit 27 - Financial Data Schedule
(b) Reports on Form 8-K:
None.
13
<PAGE> 14
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.
PharmChem Laboratories, Inc.
(Registrant)
Date: August 4, 1998 By: /s/ David A. Lattanzio
----------------------------------
David A. Lattanzio
Chief Financial Officer and Vice President,
Finance and Administration
14
<PAGE> 15
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
Number Description
- ------- -----------
<S> <C>
27 Financial Data Schedule
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> JUN-30-1998
<CASH> 604
<SECURITIES> 0
<RECEIVABLES> 8,860
<ALLOWANCES> 459
<INVENTORY> 1,570
<CURRENT-ASSETS> 11,307
<PP&E> 18,850
<DEPRECIATION> 10,814
<TOTAL-ASSETS> 23,656
<CURRENT-LIABILITIES> 12,317
<BONDS> 0
0
0
<COMMON> 19,055
<OTHER-SE> 97
<TOTAL-LIABILITY-AND-EQUITY> 23,656
<SALES> 0
<TOTAL-REVENUES> 20,979
<CGS> 0
<TOTAL-COSTS> 15,523
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 93
<INTEREST-EXPENSE> 189
<INCOME-PRETAX> 135
<INCOME-TAX> 81
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 54
<EPS-PRIMARY> 0.01
<EPS-DILUTED> 0.01
</TABLE>
